Rockwell Medical (RMTI) Projected to Release Earnings on Thursday

Rockwell Medical (NASDAQ:RMTI) is projected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Rockwell Medical to announce earnings of ($0.2350) per share and revenue of $17.82 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:00 AM ET.

Rockwell Medical Stock Down 4.2%

Shares of NASDAQ:RMTI opened at $6.84 on Tuesday. The company has a 50 day moving average of $6.43 and a two-hundred day moving average of $8.32. The company has a market capitalization of $27.15 million, a price-to-earnings ratio of -4.56 and a beta of 1.60. Rockwell Medical has a 52-week low of $4.89 and a 52-week high of $21.00. The company has a quick ratio of 3.43, a current ratio of 3.74 and a debt-to-equity ratio of 0.23.

Institutional Investors Weigh In On Rockwell Medical

Several hedge funds and other institutional investors have recently made changes to their positions in RMTI. Geode Capital Management LLC boosted its holdings in shares of Rockwell Medical by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after acquiring an additional 41,668 shares in the last quarter. XTX Topco Ltd grew its holdings in Rockwell Medical by 286.5% during the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after buying an additional 46,029 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Rockwell Medical during the fourth quarter valued at approximately $84,000. Finally, Vanguard Group Inc. raised its holdings in shares of Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after purchasing an additional 148,737 shares during the period. 23.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RMTI has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $20.00 target price (up from $2.00) on shares of Rockwell Medical in a research note on Thursday, July 9th. Weiss Ratings upgraded Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Finally, Wall Street Zen upgraded Rockwell Medical to a “hold” rating in a research report on Saturday, July 25th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.00.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.